AU2014243773B2 - Neuroactive steroids and methods of use thereof - Google Patents
Neuroactive steroids and methods of use thereof Download PDFInfo
- Publication number
- AU2014243773B2 AU2014243773B2 AU2014243773A AU2014243773A AU2014243773B2 AU 2014243773 B2 AU2014243773 B2 AU 2014243773B2 AU 2014243773 A AU2014243773 A AU 2014243773A AU 2014243773 A AU2014243773 A AU 2014243773A AU 2014243773 B2 AU2014243773 B2 AU 2014243773B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- unsubstituted
- compound
- certain embodiments
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC1(C)C=NCCC*1 Chemical compound CC1(C)C=NCCC*1 0.000 description 3
- KFNMXUHNHJZIRK-RKDJMYEQSA-N CC(C)C(C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O Chemical compound CC(C)C(C)(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)O KFNMXUHNHJZIRK-RKDJMYEQSA-N 0.000 description 2
- HEOYUTKBAGAXSP-LMDOIDTISA-N C[C@H](CC[C@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O Chemical compound C[C@H](CC[C@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@@H]1C[C@@]2(C)O HEOYUTKBAGAXSP-LMDOIDTISA-N 0.000 description 2
- VXLPTCJCHWUKKV-NFSSVYEPSA-N CCCCC1=CC[C@@H]([C@H](CC2)[C@](C)(CC3)[C@H]2[C@H](C)CCCC(F)(F)F)[C@H]3[C@@]1(C)CC Chemical compound CCCCC1=CC[C@@H]([C@H](CC2)[C@](C)(CC3)[C@H]2[C@H](C)CCCC(F)(F)F)[C@H]3[C@@]1(C)CC VXLPTCJCHWUKKV-NFSSVYEPSA-N 0.000 description 1
- NLHFJIAZBHNOSY-AMIYGGGRSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C(F)(F)F)O)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C(F)(F)F)O)O NLHFJIAZBHNOSY-AMIYGGGRSA-N 0.000 description 1
- ZKVOXHUCRWANHT-SLDOBEGXSA-N CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C)C(F)(F)F)O Chemical compound CC[C@](CC1)(C[C@H](CC2)[C@@]1(C)[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2[C@H](C)CC[C@@H](C)C(F)(F)F)O ZKVOXHUCRWANHT-SLDOBEGXSA-N 0.000 description 1
- WRWPNZJNPRSDSN-UNDMJTHNSA-N CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CC[C@H](C(F)(F)F)O)[C@H]4[C@@]2(C)CC1)O Chemical compound CC[C@]1(CC2=CC[C@@H]([C@H](CC3)[C@](C)(CC4)[C@H]3[C@H](C)CC[C@H](C(F)(F)F)O)[C@H]4[C@@]2(C)CC1)O WRWPNZJNPRSDSN-UNDMJTHNSA-N 0.000 description 1
- UDCASXDDUOLRMT-XOLAWMNISA-N C[C@H](CCC(C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 UDCASXDDUOLRMT-XOLAWMNISA-N 0.000 description 1
- HWAIKCHQQOQKDK-GHCDENFXSA-N C[C@H](CCC(C)(CCOC)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(CCOC)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 HWAIKCHQQOQKDK-GHCDENFXSA-N 0.000 description 1
- BVBRUQYHUXKZMQ-CNBKNGECSA-N C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 BVBRUQYHUXKZMQ-CNBKNGECSA-N 0.000 description 1
- WRTPCXHWTPMXCQ-LMBAJECESA-N C[C@H](CC[C@@](C)(CCCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(CCCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 WRTPCXHWTPMXCQ-LMBAJECESA-N 0.000 description 1
- UDCASXDDUOLRMT-MBOCNQOASA-N C[C@H](CC[C@@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CC[C@@](C)(CCO)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 UDCASXDDUOLRMT-MBOCNQOASA-N 0.000 description 1
- XUIXYHLPAUINEV-CVARHHIYSA-N C[C@H](CC[C@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(C)O Chemical compound C[C@H](CC[C@](C)(C(F)(F)F)O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@@]2(C)O XUIXYHLPAUINEV-CVARHHIYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019201275A AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
| AU2021200205A AU2021200205B2 (en) | 2013-03-13 | 2021-01-14 | Neuroactive steroids and methods of use thereof |
| AU2022279366A AU2022279366B2 (en) | 2013-03-13 | 2022-11-28 | Neuroactive steroids and methods of use thereof |
| AU2025203021A AU2025203021A1 (en) | 2013-03-13 | 2025-04-29 | Neuroactive steroids and methods of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779735P | 2013-03-13 | 2013-03-13 | |
| US61/779,735 | 2013-03-13 | ||
| PCT/US2014/026784 WO2014160480A1 (en) | 2013-03-13 | 2014-03-13 | Neuroactive steroids and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201275A Division AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014243773A1 AU2014243773A1 (en) | 2015-10-01 |
| AU2014243773B2 true AU2014243773B2 (en) | 2018-12-13 |
Family
ID=51625437
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014243773A Active AU2014243773B2 (en) | 2013-03-13 | 2014-03-13 | Neuroactive steroids and methods of use thereof |
| AU2019201275A Active AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
| AU2021200205A Active AU2021200205B2 (en) | 2013-03-13 | 2021-01-14 | Neuroactive steroids and methods of use thereof |
| AU2022279366A Active AU2022279366B2 (en) | 2013-03-13 | 2022-11-28 | Neuroactive steroids and methods of use thereof |
| AU2025203021A Pending AU2025203021A1 (en) | 2013-03-13 | 2025-04-29 | Neuroactive steroids and methods of use thereof |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201275A Active AU2019201275B2 (en) | 2013-03-13 | 2019-02-22 | Neuroactive steroids and methods of use thereof |
| AU2021200205A Active AU2021200205B2 (en) | 2013-03-13 | 2021-01-14 | Neuroactive steroids and methods of use thereof |
| AU2022279366A Active AU2022279366B2 (en) | 2013-03-13 | 2022-11-28 | Neuroactive steroids and methods of use thereof |
| AU2025203021A Pending AU2025203021A1 (en) | 2013-03-13 | 2025-04-29 | Neuroactive steroids and methods of use thereof |
Country Status (25)
| Country | Link |
|---|---|
| US (6) | US20160031930A1 (OSRAM) |
| EP (4) | EP3932932B8 (OSRAM) |
| JP (6) | JP6255082B2 (OSRAM) |
| CN (3) | CN112375115A (OSRAM) |
| AU (5) | AU2014243773B2 (OSRAM) |
| BR (1) | BR112015022174B1 (OSRAM) |
| CA (2) | CA2905359C (OSRAM) |
| CY (2) | CY1120934T1 (OSRAM) |
| DK (3) | DK2968369T3 (OSRAM) |
| ES (3) | ES2699445T3 (OSRAM) |
| FI (1) | FI3932932T3 (OSRAM) |
| HR (3) | HRP20181994T1 (OSRAM) |
| HU (2) | HUE055668T2 (OSRAM) |
| IL (3) | IL280068B2 (OSRAM) |
| LT (3) | LT3461834T (OSRAM) |
| MX (2) | MX362544B (OSRAM) |
| PL (3) | PL2968369T3 (OSRAM) |
| PT (3) | PT2968369T (OSRAM) |
| RS (3) | RS67266B1 (OSRAM) |
| RU (1) | RU2684103C2 (OSRAM) |
| SI (3) | SI3932932T1 (OSRAM) |
| SM (3) | SMT201800657T1 (OSRAM) |
| TR (1) | TR201817995T4 (OSRAM) |
| WO (1) | WO2014160480A1 (OSRAM) |
| ZA (1) | ZA201506729B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX336930B (es) | 2005-11-28 | 2016-02-05 | Marinus Pharmaceuticals | Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas. |
| KR101815076B1 (ko) | 2010-10-27 | 2018-01-30 | 메루스 오디오 에이피에스 | 멀티레벨 펄스폭 변조를 사용하는 오디오 증폭기 |
| JP6205362B2 (ja) | 2011-09-08 | 2017-09-27 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性のステロイド、組成物、およびそれらの使用 |
| SMT201800657T1 (it) | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| CN107405352A (zh) | 2014-10-07 | 2017-11-28 | 萨奇治疗股份有限公司 | 神经活性化合物及其使用方法 |
| SMT202100226T1 (it) * | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| EP3319610A4 (en) * | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| MX2018004376A (es) | 2015-10-16 | 2018-08-01 | Marinus Pharmaceuticals Inc | Formulaciones inyectables de neuroesteroides que contienen nanoparticulas. |
| PL3436022T3 (pl) * | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) * | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| KR102518846B1 (ko) | 2016-08-11 | 2023-04-05 | 오비드 테라퓨틱스 인크. | 간질 장애의 치료를 위한 방법 및 조성물 |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| ES2935057T3 (es) * | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| CN119350419A (zh) * | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| CN106632565A (zh) * | 2016-11-07 | 2017-05-10 | 湖南科瑞生物制药股份有限公司 | 一种合成胆固醇的新方法 |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| WO2020260558A1 (en) | 2019-06-27 | 2020-12-30 | Phenex Pharmaceuticals Ag | 3-modified iso-/isoallo-lithocholic acid derivatives or their homo-analogs for preventing and treating clostridioides difficile-associated diseases |
| CA3145923A1 (en) | 2019-08-05 | 2021-02-11 | David Czekai | Ganaxolone for use in treatment of status epilepticus |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| AU2020395254A1 (en) | 2019-12-06 | 2022-06-02 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
| BR112023023082A2 (pt) * | 2021-05-04 | 2024-01-30 | Sage Therapeutics Inc | Esteroide neuroativo para o tratamento de comprometimento cognitivo suave associado a doença de parkinson |
| JP2024520805A (ja) | 2021-06-11 | 2024-05-24 | セージ セラピューティクス， インコーポレイテッド | アルツハイマー病の治療のための神経活性ステロイド |
| US20240368214A1 (en) * | 2021-08-25 | 2024-11-07 | Sage Therapeutics, Inc. | Positive nmda-modulating compounds and methods of use thereof |
| WO2023049295A1 (en) * | 2021-09-22 | 2023-03-30 | Sage Therapeutics, Inc. | Deuterated positive nmda-modulating compounds and methods of use thereof |
| WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| KR20240134889A (ko) * | 2021-12-13 | 2024-09-10 | 세이지 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 신경활성 스테로이드 |
| CN114478672B (zh) * | 2022-01-27 | 2024-06-14 | 浙江仙居君业药业有限公司 | 一种he3286的合成方法 |
| AU2023287695A1 (en) | 2022-06-24 | 2025-02-06 | Sage Therapeutics, Inc. | Crystalline forms of a neuroactive steroid |
| WO2024015201A1 (en) | 2022-07-12 | 2024-01-18 | Sage Therapeutics, Inc. | Crystalline form of a neuroactive steroid |
| WO2024229290A1 (en) | 2023-05-02 | 2024-11-07 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of use thereof |
| WO2025227053A1 (en) * | 2024-04-25 | 2025-10-30 | Sage Therapeutics, Inc. | Nmda receptor positive allosteric modulatory compositions and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2259698A (en) | 1938-05-07 | 1941-10-21 | Rare Chemicals Inc | Physiologically effective substance and process of preparing same |
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (OSRAM) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| DE69435286D1 (de) | 1993-05-24 | 2010-05-20 | Purdue Pharma Ltd | Verfahren und zusammensetzungen zum hervorrufen von schlaf |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP0752860B1 (en) * | 1994-02-14 | 2000-08-23 | Euro-Celtique S.A. | Androstanes and pregnanes for allosteric modulation of gaba receptor |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| CA2205919A1 (en) | 1994-11-23 | 1996-05-30 | Cocensys, Inc. | Androstane and pregnane series for allosteric modulation of gaba receptor |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| DE69634039T2 (de) * | 1995-06-06 | 2005-12-08 | Euro-Celtique S.A. | Steroidderivate der Androstan- und der Pregnanreihe |
| US5792635A (en) | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US5888996A (en) | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| WO1997003677A1 (en) | 1995-07-24 | 1997-02-06 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| CA2331299A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| KR20010043558A (ko) | 1998-05-13 | 2001-05-25 | 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 | 감수분열 조절 화합물 |
| AU3701199A (en) | 1998-05-13 | 1999-11-29 | Novo Nordisk A/S | Meiosis regulating compounds |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) * | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| EP1392713B1 (en) * | 2001-05-03 | 2007-10-17 | The University of Chicago | Liver x receptor agonists |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| CA2466033A1 (en) | 2001-11-08 | 2003-05-15 | The University Of Chicago | Method of treating disorder related to high cholesterol concentration |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| PL213697B1 (pl) | 2002-03-27 | 2013-04-30 | Phytopharm Plc | Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| US20050142192A1 (en) * | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| US20070032464A1 (en) * | 2004-10-08 | 2007-02-08 | Shutsung Liao | Methods of treating cancers |
| KR101358078B1 (ko) * | 2004-11-01 | 2014-02-06 | 주식회사 유스팜인터내셔널 | 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물 |
| WO2007098281A2 (en) | 2006-02-27 | 2007-08-30 | Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| CN101164540A (zh) * | 2006-08-03 | 2008-04-23 | 中山大学 | 海洋甾体化合物在制备治疗神经元损伤药物中的应用 |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| US8273747B2 (en) | 2006-11-02 | 2012-09-25 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| PL2711371T3 (pl) | 2006-11-21 | 2018-06-29 | Asarina Pharma Ab | Zastosowanie steroidów pregnanowych i androstanowych do wytwarzania kompozycji farmaceutycznej do leczenia zaburzeń oun |
| WO2008157786A1 (en) | 2007-06-20 | 2008-12-24 | Auspex Pharmaceutical, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| WO2009059239A2 (en) | 2007-11-02 | 2009-05-07 | Mayo Foundation For Medical Education And Research | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION |
| US20110118353A1 (en) | 2007-11-06 | 2011-05-19 | N. V. Organon | Method of hormone suppression in humans |
| JP2011505357A (ja) | 2007-12-03 | 2011-02-24 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| EP2244577B1 (en) | 2008-01-25 | 2012-10-31 | Merck Sharp & Dohme Corp. | Quinolizidinone m1 receptor positive allosteric modulators |
| CN101951930A (zh) | 2008-02-19 | 2011-01-19 | 阿奈斯特药品株式会社 | 对身体功能的恢复有用的口服或经肠组合物 |
| NZ589764A (en) | 2008-05-09 | 2012-10-26 | Univ Emory | NMDA receptor antagonists for the treatment of neuropsychiatric disorders |
| CN101683348B (zh) * | 2008-09-23 | 2012-07-04 | 中山大学 | 胆甾烷-3β,5α,6β-三醇在制备神经元保护药物中的应用 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| KR20120136378A (ko) * | 2010-03-03 | 2012-12-18 | 사토리 파마슈티컬즈, 인코포레이티드 | 신경변성 질환을 치료하는데 유용한 화합물 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| WO2012142039A1 (en) | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| CA2874998A1 (en) | 2011-05-27 | 2012-12-06 | Cytocure Llc | Methods, compositions, and kits for the treatment of cancer |
| EP2736919A4 (en) | 2011-07-29 | 2015-01-14 | Univ California | NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS |
| WO2013054822A1 (en) | 2011-10-07 | 2013-04-18 | Takeda Pharmaceutical Company Limited | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| US20150119327A1 (en) | 2012-04-25 | 2015-04-30 | The Regents Of The University Of California | Drug screening platform for rett syndrome |
| WO2014025942A1 (en) | 2012-08-09 | 2014-02-13 | Emory University | Nmda receptor modulators and uses related thereto |
| WO2014028942A2 (en) | 2012-08-17 | 2014-02-20 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
| JP2016505038A (ja) | 2013-01-23 | 2016-02-18 | スファエラ ファーマ プライベート リミテッド | ミトコンドリア生合成ならびにミトコンドリア機能不全または欠乏に関連する疾患において使用するための１１β−ヒドロキシステロイドの新規の化合物 |
| EA031905B1 (ru) | 2013-01-29 | 2019-03-29 | Аптиникс Инк. | Спиролактамные модуляторы рецептора nmda и их применение |
| SMT201800657T1 (it) * | 2013-03-13 | 2019-01-11 | Sage Therapeutics Inc | Steroidi neuroattivi e loro metodi di utilizzo |
| AU2014243819A1 (en) | 2013-03-13 | 2015-10-01 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| EP3102230B1 (en) | 2014-02-08 | 2021-04-28 | F. Hoffmann-La Roche AG | Methods of treating alzheimer's disease |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| CN107405352A (zh) | 2014-10-07 | 2017-11-28 | 萨奇治疗股份有限公司 | 神经活性化合物及其使用方法 |
| EP3319610A4 (en) | 2015-07-06 | 2019-03-06 | Sage Therapeutics, Inc. | OXYSTEROLS AND METHOD OF USE THEREOF |
| SG10202002655VA (en) | 2015-07-06 | 2020-05-28 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| SMT202100226T1 (it) | 2015-07-06 | 2021-05-07 | Sage Therapeutics Inc | Ossisteroli e metodi di uso degli stessi |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| PL3436022T3 (pl) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oksysterole i sposoby ich stosowania |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| HUE055263T2 (hu) | 2016-07-07 | 2021-11-29 | Sage Therapeutics Inc | 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| ES2935057T3 (es) | 2016-09-30 | 2023-03-01 | Sage Therapeutics Inc | C7 oxisteroles sustituidos y estos compuestos para su uso como moduladores de la NMDA |
| CN119350419A (zh) | 2016-10-18 | 2025-01-24 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| ES3038660T3 (en) | 2016-10-18 | 2025-10-14 | Sage Therapeutics Inc | Oxysterols and methods of use thereof |
| AU2018234828A1 (en) | 2017-03-15 | 2019-09-19 | Modernatx, Inc. | Lipid nanoparticle formulation |
| CN110945006A (zh) | 2017-06-23 | 2020-03-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2014
- 2014-03-13 SM SM20180657T patent/SMT201800657T1/it unknown
- 2014-03-13 SM SM20250336T patent/SMT202500336T1/it unknown
- 2014-03-13 HR HRP20181994TT patent/HRP20181994T1/hr unknown
- 2014-03-13 US US14/775,678 patent/US20160031930A1/en not_active Abandoned
- 2014-03-13 BR BR112015022174-2A patent/BR112015022174B1/pt active IP Right Grant
- 2014-03-13 HR HRP20251221TT patent/HRP20251221T1/hr unknown
- 2014-03-13 ES ES14774060T patent/ES2699445T3/es active Active
- 2014-03-13 RS RS20250988A patent/RS67266B1/sr unknown
- 2014-03-13 AU AU2014243773A patent/AU2014243773B2/en active Active
- 2014-03-13 PL PL14774060T patent/PL2968369T3/pl unknown
- 2014-03-13 EP EP21172859.7A patent/EP3932932B8/en active Active
- 2014-03-13 SI SI201432115T patent/SI3932932T1/sl unknown
- 2014-03-13 MX MX2015012430A patent/MX362544B/es active IP Right Grant
- 2014-03-13 ES ES21172859T patent/ES3042115T3/es active Active
- 2014-03-13 CN CN202011101409.4A patent/CN112375115A/zh active Pending
- 2014-03-13 EP EP25189422.6A patent/EP4643945A2/en active Pending
- 2014-03-13 CN CN202410694955.5A patent/CN118702755A/zh active Pending
- 2014-03-13 DK DK14774060.9T patent/DK2968369T3/en active
- 2014-03-13 MX MX2019000995A patent/MX388210B/es unknown
- 2014-03-13 DK DK21172859.7T patent/DK3932932T3/da active
- 2014-03-13 PT PT14774060T patent/PT2968369T/pt unknown
- 2014-03-13 LT LTEP18190034.1T patent/LT3461834T/lt unknown
- 2014-03-13 LT LTEP14774060.9T patent/LT2968369T/lt unknown
- 2014-03-13 SM SM20210475T patent/SMT202100475T1/it unknown
- 2014-03-13 RS RS20181442A patent/RS58166B1/sr unknown
- 2014-03-13 EP EP18190034.1A patent/EP3461834B1/en active Active
- 2014-03-13 LT LTEP21172859.7T patent/LT3932932T/lt unknown
- 2014-03-13 IL IL280068A patent/IL280068B2/en unknown
- 2014-03-13 PL PL18190034T patent/PL3461834T3/pl unknown
- 2014-03-13 HU HUE18190034A patent/HUE055668T2/hu unknown
- 2014-03-13 JP JP2016502244A patent/JP6255082B2/ja active Active
- 2014-03-13 IL IL318314A patent/IL318314A/en unknown
- 2014-03-13 DK DK18190034.1T patent/DK3461834T3/da active
- 2014-03-13 PT PT211728597T patent/PT3932932T/pt unknown
- 2014-03-13 SI SI201430981T patent/SI2968369T1/sl unknown
- 2014-03-13 RS RS20211011A patent/RS62235B1/sr unknown
- 2014-03-13 CA CA2905359A patent/CA2905359C/en active Active
- 2014-03-13 EP EP14774060.9A patent/EP2968369B1/en active Active
- 2014-03-13 HU HUE21172859A patent/HUE072324T2/hu unknown
- 2014-03-13 ES ES18190034T patent/ES2886506T3/es active Active
- 2014-03-13 FI FIEP21172859.7T patent/FI3932932T3/fi active
- 2014-03-13 CA CA3114062A patent/CA3114062A1/en not_active Abandoned
- 2014-03-13 WO PCT/US2014/026784 patent/WO2014160480A1/en not_active Ceased
- 2014-03-13 CN CN201480026165.4A patent/CN105246486B/zh active Active
- 2014-03-13 RU RU2015143466A patent/RU2684103C2/ru active
- 2014-03-13 SI SI201431866T patent/SI3461834T1/sl unknown
- 2014-03-13 PL PL21172859.7T patent/PL3932932T3/pl unknown
- 2014-03-13 TR TR2018/17995T patent/TR201817995T4/en unknown
- 2014-03-13 PT PT181900341T patent/PT3461834T/pt unknown
-
2015
- 2015-09-08 IL IL241301A patent/IL241301B/en active IP Right Grant
- 2015-09-10 ZA ZA2015/06729A patent/ZA201506729B/en unknown
-
2017
- 2017-05-05 US US15/588,305 patent/US20170305960A1/en not_active Abandoned
- 2017-12-01 JP JP2017231660A patent/JP6530804B2/ja active Active
-
2018
- 2018-03-09 US US15/917,263 patent/US10227375B2/en active Active
- 2018-11-27 CY CY181101258T patent/CY1120934T1/el unknown
- 2018-12-20 US US16/227,013 patent/US11104701B2/en active Active
-
2019
- 2019-02-22 AU AU2019201275A patent/AU2019201275B2/en active Active
- 2019-05-17 JP JP2019093816A patent/JP2019135261A/ja not_active Withdrawn
-
2021
- 2021-01-14 AU AU2021200205A patent/AU2021200205B2/en active Active
- 2021-07-05 JP JP2021111379A patent/JP7317898B2/ja active Active
- 2021-07-21 US US17/381,829 patent/US11905309B2/en active Active
- 2021-08-10 CY CY20211100713T patent/CY1124629T1/el unknown
- 2021-08-12 HR HRP20211300TT patent/HRP20211300T1/hr unknown
-
2022
- 2022-10-03 JP JP2022159468A patent/JP7715692B2/ja active Active
- 2022-11-28 AU AU2022279366A patent/AU2022279366B2/en active Active
-
2024
- 2024-01-05 US US18/405,657 patent/US20240287125A1/en active Pending
-
2025
- 2025-04-29 AU AU2025203021A patent/AU2025203021A1/en active Pending
- 2025-06-05 JP JP2025094024A patent/JP2025120299A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036835A1 (en) * | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
Non-Patent Citations (4)
| Title |
|---|
| CONNICK J H ET AL, "Org (1) potentiates NMDA-receptor mediated responses in vivo", 2009 NEUROSCIENCE MEETING PLANNER. CHICAGO, IL; OCTOBER 17 - 21, 2009, SOCIETY FOR NEUROSCIENCE, (2009-10-17), no. Program#/Poster#: 613 1/B86, pages 1 - 2 * |
| S. M. PAUL ET AL, "The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-D-Aspartate Receptors", JOURNAL OF NEUROSCIENCE, US, (2013-10-30), vol. 33, no. 44, pages 17290 - 17300 * |
| XILOURI ET AL, "Neuroprotective effects of steroid analogues on P19-N neurons", NEUROCHEMISTRY INTERNATIONAL, PERGAMON PRESS, OXFORD, GB, (2007-03-02), vol. 50, no. 4, doi:10.1016/J.NEUINT.2006.12.010, ISSN 0197-0186, pages 660 - 670 * |
| YOON-SEOK ROH ET AL, "Neuroprotective Effects of Ginsenoside Rg 3 against 24-OH-cholesterol-induced Cytotoxicity in Cortical Neurons", JOURNAL OF GINSENG RESEARCH, KR, (2010-09-30), vol. 34, no. 3, pages 246 - 253 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014243773B2 (en) | Neuroactive steroids and methods of use thereof | |
| HK40066987A (en) | Neuroactive steriods and methods of use thereof | |
| HK40007016A (en) | Neuroactive steroids | |
| HK40007016B (en) | Neuroactive steroids | |
| RU2808166C2 (ru) | Нейроактивные стероиды и способы их применения | |
| HK1220375B (en) | Neuroactive steroids and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |